Have a question?
Please get in touch with our team in case of any queries
THE AI IN DRUG DISCOVERY MARKET SIZE IS EXPECTED TO REACH USD 8.52 BILLION BY 2030 FROM USD 1.71 BILLION IN 2024, GROWING AT A CAGR OF 30.58% DURING THE FORECAST PERIOD.
The Global AI In Drug Discovery Market Size, Share, & Trends Analysis Report By
- Application: Drug Repurposing, Drug Screening, Drug Design & Optimization, and Others
- Therapeutic Area: Oncological Disorders, CNS Disorders, Infectious Diseases, Immunological Disorders, Cardiovascular Disorders, Gastrointestinal Disorders, and Others
- Drug Type: Small Molecule and Biologics
- Technology: Machine Learning (ML), Deep Learning, Natural Language Processing (NLP), and Others
- End-user: Pharma & Biotech Companies, CROs & CDMOs, and Others
- Geography: North America, Europe, APAC, Latin America, and Middle East & Africa
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2025–2030.
This report includes market data points, ranging from trend
analyses to market estimates & forecasts that you can customize
AI IN DRUG DISCOVERY MARKET REPORT SCOPE
| REPORT ATTRIBUTE | DETAILS |
|---|---|
| MARKET SIZE (2030) | USD 8.52 Billion |
| MARKET SIZE (2024) | USD 1.71 Billion |
| CAGR (2024-2030) | 30.58% |
| HISTORIC YEAR | 2021-2023 |
| BASE YEAR | 2024 |
| FORECAST YEAR | 2025-2030 |
| SEGMENTS BY | Application, Therapeutic Area, Drug Type, Technology, End-user, and Geography |
| GEOGRAPHIC ANALYSIS | North America, Europe, APAC, Latin America, and Middle East & Africa |
| KEY PLAYERS | Atomwise, Amazon Web Services (AWS), BenevolentAI, Google, IBM, Insilico Medicine, Microsoft, NVIDIA, and Recursion Pharmaceuticals |
MARKET OVERVIEW
The global AI in drug discovery market size was valued at USD 1.71 billion in 2024 and is expected to reach USD 8.52 billion by 2030, growing at a CAGR of 30.58% during the forecast period. The market is poised for exponential growth, driven by technological advancements, increasing investments, and a growing focus on precision medicine. As AI algorithms continue to evolve, they are expected to play an even greater role in addressing the inefficiencies of traditional drug discovery processes. Companies that prioritize innovation, collaboration, and regulatory alignment will be well-positioned to capitalize on the vast opportunities in this dynamic market.
The global artificial intelligence (AI) in the drug discovery market has emerged as a transformative force, revolutionizing the pharmaceutical and biotechnology industries. AI technologies are reshaping the traditional drug discovery process by accelerating timelines, reducing costs, and enhancing precision. Pharmaceutical companies are increasingly adopting AI to streamline drug discovery and development processes. AI-driven platforms enable faster identification of drug candidates, optimize molecular screening, and predict clinical outcomes with higher accuracy. This trend is fueled by the industry's need to combat high R&D costs and lengthy drug development cycles. Also, by leveraging the potential of AI, the pharmaceutical industry can accelerate the development of life-saving therapies, reduce healthcare costs, and improve patient outcomes on a global scale.
MARKET TRENDS & DRIVERS
Integration of AI with Big Data and Omics Technologies
The integration of AI with big data and omics technologies is reshaping the global drug discovery market. By enabling a deeper understanding of biological systems, improving efficiency, and driving personalized medicine, this trend is creating unprecedented opportunities for innovation and growth. Overcoming existing challenges will further cement its role as a transformative force in the healthcare and pharmaceutical industries. The future of drug discovery is undeniably data-driven, with AI at its core.
Increasing Use of Generative AI Models
The increasing use of generative AI models in the global AI in drug discovery market marks a paradigm shift in how pharmaceutical research and development are conducted. By enabling faster, cheaper, and more precise drug development, these models are creating new opportunities across the healthcare ecosystem. As technology continues to evolve, generative AI is set to redefine the boundaries of what is possible in drug discovery, offering hope for faster cures, more personalized treatments, and a healthier future.
Emergence of AI-Driven Drug Repurposing
The emergence of AI-driven drug repurposing is a game-changer in the global drug discovery market, transforming traditional approaches and creating exciting new opportunities. By reducing costs, accelerating timelines, and addressing unmet medical needs, AI-driven drug repurposing is shaping the future of pharmaceutical innovation. As AI technologies continue to evolve, their integration into drug repurposing will undoubtedly unlock even greater potential, benefiting both the industry and global healthcare systems.
Growing Partnerships between Pharmaceutical Companies and AI-focused Expertise
The growing partnerships between pharmaceutical companies and AI-focused expertise are transforming the global drug discovery landscape. By leveraging AI's capabilities to overcome traditional challenges, these collaborations are creating new opportunities for faster, more cost-effective, and innovative drug development. As the pharmaceutical industry continues to embrace AI, the synergies between these two domains will not only drive market growth but also pave the way for groundbreaking advancements in medicine, ultimately benefiting patients worldwide.
Advancements in Computing Power and Cloud Technologies
The convergence of computing power and cloud technologies has become a driving force in the global AI in drug discovery market. These advancements are empowering pharmaceutical companies and research institutions to revolutionize drug development processes, making them faster, more efficient, and more accessible. As technology continues to evolve, the synergy between AI, computing, and cloud platforms will play an increasingly central role in addressing unmet medical needs and advancing healthcare innovation worldwide.
Rising R&D Costs in Drug Discovery
The rising costs of R&D in drug discovery are pushing the pharmaceutical industry to embrace innovative solutions, and AI is emerging as a powerful enabler. By reducing expenses, improving success rates, and accelerating development timelines, AI is addressing critical pain points in the industry. As the global AI in drug discovery market continues to expand, it holds the potential to not only alleviate financial pressures but also revolutionize healthcare by delivering innovative treatments more efficiently and effectively.
Growing Volume of Biological and Clinical Data
The growing volume of biological and clinical data is a driving force in the global AI in drug discovery market. By enabling the analysis of vast and complex datasets, AI is revolutionizing target identification, drug screening, and personalized medicine. Although challenges remain, the synergy between AI and data promises to unlock new frontiers in drug discovery, improving global health outcomes and addressing unmet medical needs. As this trend continues, AI will remain at the forefront of innovation, reshaping the pharmaceutical landscape.
Increasing Prevalence of Chronic Diseases
The increasing prevalence of chronic diseases has created a pressing need for innovative and efficient drug discovery methods. AI has emerged as a transformative tool, enabling the rapid identification of potential drug candidates, optimizing clinical trials, and accelerating the development of personalized therapies. As chronic diseases continue to rise globally, the adoption of AI in drug discovery is poised to grow, driving advancements in healthcare and improving patient outcomes. With continued investments and collaborations, the global AI in drug discovery market is set to play a pivotal role in addressing one of the most significant healthcare challenges of our time.
SEGMENTATION INSIGHTS
INSIGHTS BY APPLICATION
The global AI in drug discovery market by application is segmented into drug repurposing, drug screening, drug design & optimization, and others. The drug repurposing segment held the largest market share. Drug repurposing refers to the identification of new therapeutic uses for existing drugs. AI significantly enhances this process by analyzing massive datasets, including genomics, clinical trials, and real-world evidence, to identify potential drug-disease pairings. Drug screening involves the evaluation of thousands of compounds to identify potential candidates for further development. AI-powered screening significantly accelerates this traditionally time-intensive process.
AI is revolutionizing drug design and optimization by generating novel molecular structures and refining existing compounds for improved efficacy, safety, and pharmacokinetics. Beyond the core applications, AI is being deployed in various other aspects of drug discovery, such as clinical trial optimization, biomarker discovery, and toxicity prediction. Furthermore, the global AI in drug discovery market is expected to witness sustained growth across all applications. Advances in AI technologies, increasing adoption of cloud computing, and deeper integration of AI into the pharmaceutical pipeline will drive innovation and efficiency. As more companies and research institutions embrace AI-driven approaches, the potential to bring safer, more effective therapies to market faster and at a lower cost is becoming a reality.
INSIGHTS BY THERAPEUTIC AREA
The global AI in drug discovery market spans various therapeutic areas, leveraging AI to enhance research and development across diverse medical conditions. AI's ability to analyze vast datasets, identify potential drug candidates, and streamline development pipelines has significantly impacted therapeutic segments, addressing critical healthcare challenges. In 2024, the oncological disorders therapeutic area segment held the largest global AI in drug discovery market share. One of the primary applications of AI in oncological drug discovery is in identifying novel therapeutic targets. AI-powered algorithms analyze genomic and transcriptomic data to pinpoint genes and proteins involved in tumor progression. Furthermore, the integration of multi-omics data improved predictive analytics, and collaboration between stakeholders will further enhance therapeutic innovation, shaping the future of drug discovery worldwide.
INSIGHTS BY DRUG TYPE
The small molecule drug type holds the most significant share of the global AI in drug discovery market, largely due to their established role in treating a broad range of diseases. These drugs are chemically synthesized, relatively inexpensive to manufacture, and have a proven track record in pharmaceutical applications. AI tools like generative models and machine learning algorithms are extensively used to design and optimize small molecule drugs by predicting their interactions with biological targets, toxicity profiles, and pharmacokinetics. Biologics, including monoclonal antibodies, vaccines, and gene therapies, are gaining traction due to their specificity and efficacy in targeting complex diseases. AI technologies like neural networks are employed to analyze biological data, identify novel protein structures, and optimize biologics’ development.
INSIGHTS BY TECHNOLOGY
The global AI in drug discovery market by technology is segmented into machine learning (ML), deep learning, natural language processing (NLP), and others. The machine learning (ML) segment holds the largest market share in 2024. ML is the most widely used technology in AI-driven drug discovery. It enables the analysis of large datasets, identifies hidden patterns, and accelerates the drug development process. Its ability to process vast amounts of structured and unstructured data makes it indispensable for drug discovery. Also, machine learning also plays a critical role in optimizing clinical trial design and execution. By analyzing patient data, ML algorithms can identify suitable patient cohorts for trials, predict patient responses, and reduce dropout rates.
Deep learning uses artificial neural networks to analyze highly complex data, such as genomics, proteomics, and imaging. The deep learning segment is also projected to witness significant growth during the forecast period. Deep learning is particularly useful in structure-based drug design, biomarker discovery, and disease pathway analysis. Moreover, deep learning facilitates lead optimization by predicting the pharmacokinetics and toxicity profiles of drug candidates. Predictive models trained on historical data help refine chemical structures to enhance efficacy, safety, and bioavailability. This minimizes the chances of late-stage failures, a common challenge in traditional drug development.
INSIGHTS BY END-USER
The global AI in drug discovery market by end-user is segmented into pharma & biotech companies, CROs & CDMOs, and others. The increasing adoption of AI across all end-user segments reflects the growing recognition of its transformative potential in drug discovery. Pharma & biotech companies will continue to lead the market, leveraging AI to address R&D inefficiencies and enhance drug pipelines. As AI technologies continue to advance, the role of pharma and biotech companies as end-users will be instrumental in shaping the future of medicine, addressing unmet medical needs, and improving global health outcomes. Meanwhile, CROs & CDMOs will see steady growth due to the rise in outsourcing trends, and academic institutions will remain pivotal in driving fundamental innovations. Government organizations will focus on fostering a regulatory and infrastructural environment conducive to AI adoption, ensuring the market's sustained expansion.
GEOGRAPHICAL ANALYSIS
The global AI in drug discovery market exhibits significant regional diversity, with each geography offering unique opportunities and challenges. North America leads the global AI in drug discovery market accounting for a global share of over 43% in 2024, driven by its advanced technological ecosystem, robust pharmaceutical and biotechnology sectors, and substantial investments in research and development. The region is home to key players, innovative startups, and extensive academic and research collaborations that position it at the forefront of AI adoption in drug discovery. Also, the U.S. is home to leading AI companies, research institutions, and pharmaceutical giants, fostering a strong ecosystem for AI integration in drug discovery. Companies such as IBM Watson, NVIDIA, and Google DeepMind are collaborating with pharmaceutical firms to accelerate AI-driven drug development.
Europe holds a significant share in the AI in drug discovery market, driven by its strong research networks, public-private partnerships, and supportive regulatory frameworks. European countries focus on secure data sharing and ethical AI deployment, supported by frameworks like GDPR. This ensures the responsible use of patient data in drug development. Also, strong Biotech Sector: Countries like Germany, France, and the UK are at the forefront of AI-driven drug discovery, with a thriving biotech industry and state-of-the-art research facilities.
Furthermore, the APAC region is witnessing exponential growth in the AI in drug discovery market, fueled by increasing healthcare investments, a growing pharmaceutical sector, and government support. Countries like China, Japan, and India have launched national AI strategies to boost innovation in drug discovery. For instance, China’s “Next Generation Artificial Intelligence Development Plan” prioritizes AI integration across healthcare. Furthermore, the Middle East, Africa, and Latin America represent nascent but promising markets driven by government support and increasing investments in healthcare innovation. These regional dynamics collectively contribute to the global market's expansion, underscoring the transformative potential of AI in revolutionizing drug discovery.
VENDOR LANDSCAPE
The global AI in drug discovery market has witnessed significant growth in recent years as pharmaceutical companies increasingly adopt AI to accelerate and optimize drug discovery processes. AI-powered technologies, including machine learning (ML), deep learning, and natural language processing (NLP), are enabling researchers to navigate the complexity of biological systems, analyze vast biomedical datasets, and identify promising drug candidates faster and at reduced costs. The competitive landscape of the global AI in drug discovery market is marked by the presence of established pharmaceutical companies, AI technology providers, and emerging startups, all vying to gain a foothold in this rapidly evolving domain. Moreover, companies like IBM Watson Health, Google DeepMind, and NVIDIA, are significant players in the AI in drug discovery market offering advanced AI platforms tailored for drug discovery. For instance, IBM Watson leverages natural language processing and machine learning to mine scientific literature and identify drug targets. Google DeepMind, through its AlphaFold system, has revolutionized protein structure prediction, enabling faster and more precise identification of potential drug candidates.
Leading pharmaceutical firms such as Pfizer, Novartis, Roche, and AstraZeneca have incorporated AI technologies into their research pipelines. These companies are increasingly collaborating with AI startups to drive innovation. For example, AstraZeneca partnered with BenevolentAI to leverage machine learning algorithms for target identification and drug repurposing, showcasing the synergistic potential of AI in pharmaceutical R&D. Furthermore, startups and specialized AI companies, such as BenevolentAI, Insilico Medicine, Atomwise, Exscientia, and Recursion Pharmaceuticals, are at the forefront in the AI in drug discovery market. These companies have developed AI algorithms capable of analyzing complex biological data, predicting molecular interactions, and accelerating preclinical drug discovery stages.
SNAPSHOT
The global AI in drug discovery market size is expected to grow at a CAGR of approximately 30.58% from 2024 to 2030.
The following factors are likely to contribute to the growth of the AI in drug discovery market during the forecast period:
- Advancements in Computing Power and Cloud Technologies
- Rising R&D Costs in Drug Discovery
- Growing Volume of Biological and Clinical Data
- Increasing Prevalence of Chronic Diseases
Base Year: 2024
Forecast Year: 2025-2030
The report considers the present scenario of the global AI in drug discovery market and its market dynamics for 2025−2030. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes leading companies and several other prominent companies operating in the market.
Key Company Profiles
- Atomwise
- Business Overview
- Product Offerings
- Key Strategies
- Key Strengths
- Key Opportunities
- Amazon Web Services (AWS)
- BenevolentAI
- IBM
- Insilico Medicine
- Microsoft
- NVIDIA
- Recursion Pharmaceuticals
Other Prominent Vendors
- AbCellera
- Business Overview
- Product Offerings
- Aitia
- BenchSci
- BioSymetrics
- BPGbio
- Centella
- Envisagenics
- EVAXION Biotech A/S
- Iktos
- Illumina
- insitro
- Merck KGaA
- Model Medicine
- NuMedii
- Owkin
- Predictive Oncology
- Relay Therapeutics
- Standigm
- Valo Health
- Verge Genomics
- XtalPi
Segmentation by Application
- Drug Repurposing
- Drug Screening
- Drug Design & Optimization
- Others
Segmentation by Therapeutic Area
- Oncological Disorders
- CNS Disorders
- Infectious Diseases
- Immunological Disorders
- Cardiovascular Disorders
- Gastrointestinal Disorders
- Others
Segmentation by Drug Type
- Small Molecule
- Biologics
Segmentation by Technology
- Machine Learning (ML)
- Deep Learning
- Natural Language Processing (NLP)
- Others
Segmentation by End-user
- Pharma & Biotech Companies
- Contract Research Organizations (CROs) & Contract Development and Manufacturing Organizations (CDMOs)
- Others
Segmentation by Geography
- North America
- The U.S.
- Canada
- Europe
- Germany
- The U.K.
- Switzerland
- France
- Italy
- Spain
- Netherlands
- APAC
- China
- Japan
- India
- South Korea
- Australia
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Middle East & Africa
- Turkey
- South Africa
- Saudi Arabia
- UAE
Frequently Asked Questions
How big is the global AI in drug discovery market?
What is the growth rate of the global AI in drug discovery market?
Which region dominates the global AI in drug discovery market share?
What are the significant trends in the AI in drug discovery industry?
Who are the key players in the global AI in drug discovery market?
EXHIBIT 1 MARKET SIZE CALCULATION APPROACH 2024
EXHIBIT 2 GLOBAL AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024 & 2030 (% SHARE)
EXHIBIT 3 GLOBAL AI IN DRUG DISCOVERY MARKET BY APPLICATION 2024 & 2030 (% SHARE)
EXHIBIT 4 GLOBAL AI IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA 2024 & 2030 (% SHARE)
EXHIBIT 5 GLOBAL AI IN DRUG DISCOVERY MARKET BY DRUG TYPE 2024 & 2030 (% SHARE)
EXHIBIT 6 GLOBAL AI IN DRUG DISCOVERY MARKET BY TECHNOLOGY 2024 & 2030 (% SHARE)
EXHIBIT 7 GLOBAL AI IN DRUG DISCOVERY MARKET BY END-USER 2024 & 2030 (% SHARE)
EXHIBIT 8 IMPACT OF INTEGRATION OF AI WITH BIG DATA AND OMICS TECHNOLOGIES
EXHIBIT 9 IMPACT OF INCREASE IN USE OF GENERATIVE AI MODELS
EXHIBIT 10 IMPACT OF EMERGENCE OF AI-DRIVEN DRUG REPURPOSING
EXHIBIT 11 IMPACT OF GROWTH IN PARTNERSHIPS BETWEEN PHARMACEUTICAL COMPANIES AND AI-FOCUSED EXPERTISE
EXHIBIT 12 IMPACT OF ADVANCES IN COMPUTING POWER AND CLOUD TECHNOLOGIES
EXHIBIT 13 IMPACT OF RISE IN R&D COSTS IN DRUG DISCOVERY
EXHIBIT 14 IMPACT OF GROWTH IN VOLUME OF BIOLOGICAL AND CLINICAL DATA
EXHIBIT 15 IMPACT OF INCREASE IN PREVALENCE OF CHRONIC DISEASES
EXHIBIT 16 IMPACT OF HIGH INITIAL COSTS OF AI IMPLEMENTATION
EXHIBIT 17 IMPACT OF DATA PRIVACY AND SECURITY CONCERNS
EXHIBIT 18 IMPACT OF REGULATORY AND ETHICAL CHALLENGES
EXHIBIT 19 GLOBAL AI IN DRUG DISCOVERY MARKET 2021–2030 ($ MILLION)
EXHIBIT 20 FIVE FORCES ANALYSIS 2024
EXHIBIT 21 INCREMENTAL GROWTH BY APPLICATION 2024 & 2030
EXHIBIT 22 GLOBAL AI IN DRUG DISCOVERY MARKET BY APPLICATION 2024-2030: INCREMENTAL GROWTH ($ MILLION)
EXHIBIT 23 GLOBAL AI IN DRUG DISCOVERY MARKET BY APPLICATION 2024-2030: ABSOLUTE GROWTH (%)
EXHIBIT 24 GLOBAL DRUG REPURPOSING AI IN DRUG DISCOVERY MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 25 GLOBAL DRUG REPURPOSING AI IN DRUG DISCOVERY MARKET 2021-2030 ($ MILLION)
EXHIBIT 26 GLOBAL DRUG SCREENING AI IN DRUG DISCOVERY MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 27 GLOBAL DRUG SCREENING AI IN DRUG DISCOVERY MARKET 2021-2030 ($ MILLION)
EXHIBIT 28 GLOBAL DRUG DESIGN & OPTIMIZATION AI IN DRUG DISCOVERY MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 29 GLOBAL DRUG DESIGN & OPTIMIZATION AI IN DRUG DISCOVERY MARKET 2021-2030 ($ MILLION)
EXHIBIT 30 GLOBAL OTHERS AI IN DRUG DISCOVERY MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 31 GLOBAL OTHERS AI IN DRUG DISCOVERY MARKET 2021-2030 ($ MILLION)
EXHIBIT 32 INCREMENTAL GROWTH BY THERAPEUTIC AREA 2024 & 2030
EXHIBIT 33 GLOBAL AI IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA 2024-2030: INCREMENTAL GROWTH ($ MILLION)
EXHIBIT 34 GLOBAL AI IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA 2024-2030: ABSOLUTE GROWTH (%)
EXHIBIT 35 GLOBAL ONCOLOGICAL DISORDERS AI IN DRUG DISCOVERY MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 36 GLOBAL ONCOLOGICAL DISORDERS AI IN DRUG DISCOVERY MARKET 2021-2030 ($ MILLION)
EXHIBIT 37 GLOBAL CNS DISORDERS AI IN DRUG DISCOVERY MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 38 GLOBAL CNS DISORDERS AI IN DRUG DISCOVERY MARKET 2021-2030 ($ MILLION)
EXHIBIT 39 GLOBAL INFECTIOUS DISEASES AI IN DRUG DISCOVERY MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 40 GLOBAL INFECTIOUS DISEASES AI IN DRUG DISCOVERY MARKET 2021-2030 ($ MILLION)
EXHIBIT 41 GLOBAL IMMUNOLOGICAL DISORDERS AI IN DRUG DISCOVERY MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 42 GLOBAL IMMUNOLOGICAL DISORDERS AI IN DRUG DISCOVERY MARKET 2021-2030 ($ MILLION)
EXHIBIT 43 GLOBAL CARDIOVASCULAR DISORDERS AI IN DRUG DISCOVERY MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 44 GLOBAL CARDIOVASCULAR DISORDERS AI IN DRUG DISCOVERY MARKET 2021-2030 ($ MILLION)
EXHIBIT 45 GLOBAL GASTROINTESTINAL DISORDERS AI IN DRUG DISCOVERY MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 46 GLOBAL GASTROINTESTINAL DISORDERS AI IN DRUG DISCOVERY MARKET 2021-2030 ($ MILLION)
EXHIBIT 47 GLOBAL OTHERS AI IN DRUG DISCOVERY MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 48 GLOBAL OTHERS AI IN DRUG DISCOVERY MARKET 2021-2030 ($ MILLION)
EXHIBIT 49 INCREMENTAL GROWTH BY DRUG TYPE 2024 & 2030
EXHIBIT 50 GLOBAL AI IN DRUG DISCOVERY MARKET BY DRUG TYPE 2024-2030: INCREMENTAL GROWTH ($ MILLION)
EXHIBIT 51 GLOBAL AI IN DRUG DISCOVERY MARKET BY DRUG TYPE 2024-2030: ABSOLUTE GROWTH (%)
EXHIBIT 52 GLOBAL SMALL MOLECULE AI IN DRUG DISCOVERY MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 53 GLOBAL SMALL MOLECULE AI IN DRUG DISCOVERY MARKET 2021-2030 ($ MILLION)
EXHIBIT 54 GLOBAL BIOLOGICS AI IN DRUG DISCOVERY MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 55 GLOBAL BIOLOGICS AI IN DRUG DISCOVERY MARKET 2021-2030 ($ MILLION)
EXHIBIT 56 INCREMENTAL GROWTH BY TECHNOLOGY 2024 & 2030
EXHIBIT 57 GLOBAL AI IN DRUG DISCOVERY MARKET BY TECHNOLOGY 2024-2030: INCREMENTAL GROWTH ($ MILLION)
EXHIBIT 58 GLOBAL AI IN DRUG DISCOVERY MARKET BY TECHNOLOGY 2024-2030: ABSOLUTE GROWTH (%)
EXHIBIT 59 GLOBAL MACHINE LEARNING AI IN DRUG DISCOVERY MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 60 GLOBAL MACHINE LEARNING AI IN DRUG DISCOVERY MARKET 2021-2030 ($ MILLION)
EXHIBIT 61 GLOBAL DEEP LEARNING AI IN DRUG DISCOVERY MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 62 GLOBAL DEEP LEARNING AI IN DRUG DISCOVERY MARKET 2021-2030 ($ MILLION)
EXHIBIT 63 GLOBAL NATURAL LANGUAGE PROCESSING AI IN DRUG DISCOVERY MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 64 GLOBAL NATURAL LANGUAGE PROCESSING AI IN DRUG DISCOVERY MARKET 2021-2030 ($ MILLION)
EXHIBIT 65 GLOBAL OTHERS AI IN DRUG DISCOVERY MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 66 GLOBAL OTHERS AI IN DRUG DISCOVERY MARKET 2021-2030 ($ MILLION)
EXHIBIT 67 INCREMENTAL GROWTH BY END-USER 2024 & 2030
EXHIBIT 68 GLOBAL AI IN DRUG DISCOVERY MARKET BY END-USER 2024-2030: INCREMENTAL GROWTH ($ MILLION)
EXHIBIT 69 GLOBAL AI IN DRUG DISCOVERY MARKET BY END-USER 2024-2030: ABSOLUTE GROWTH (%)
EXHIBIT 70 GLOBAL PHARMA & BIOTECH COMPANIES AI IN DRUG DISCOVERY MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 71 GLOBAL PHARMA & BIOTECH COMPANIES AI IN DRUG DISCOVERY MARKET 2021-2030 ($ MILLION)
EXHIBIT 72 GLOBAL CROS & CDMOS AI IN DRUG DISCOVERY MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 73 GLOBAL CROS & CDMOS AI IN DRUG DISCOVERY MARKET 2021-2030 ($ MILLION)
EXHIBIT 74 GLOBAL OTHERS AI IN DRUG DISCOVERY MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 75 GLOBAL OTHERS AI IN DRUG DISCOVERY MARKET 2021-2030 ($ MILLION)
EXHIBIT 76 INCREMENTAL GROWTH BY GEOGRAPHY 2024 & 2030
EXHIBIT 77 GLOBAL AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024-2030: INCREMENTAL GROWTH ($ MILLION)
EXHIBIT 78 GLOBAL AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024-2030: ABSOLUTE GROWTH (%)
EXHIBIT 79 NORTH AMERICA AI IN DRUG DISCOVERY MARKET: KEY COUNTRIES IN 2024 ($ MILLION)
EXHIBIT 80 NORTH AMERICA AI IN DRUG DISCOVERY MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 81 NORTH AMERICA AI IN DRUG DISCOVERY MARKET 2021–2030 ($ MILLION)
EXHIBIT 82 INCREMENTAL GROWTH IN NORTH AMERICA 2024 & 2030
EXHIBIT 83 US AI IN DRUG DISCOVERY MARKET 2021–2030 ($ MILLION)
EXHIBIT 84 CANADA AI IN DRUG DISCOVERY MARKET 2021–2030 ($ MILLION)
EXHIBIT 85 EUROPE AI IN DRUG DISCOVERY MARKET: KEY COUNTRIES IN 2024 ($ MILLION)
EXHIBIT 86 EUROPE AI IN DRUG DISCOVERY MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 87 EUROPE AI IN DRUG DISCOVERY MARKET 2021–2030 ($ MILLION)
EXHIBIT 88 INCREMENTAL GROWTH IN EUROPE 2024 & 2030
EXHIBIT 89 GERMANY AI IN DRUG DISCOVERY MARKET 2021–2030 ($ MILLION)
EXHIBIT 90 UK AI IN DRUG DISCOVERY MARKET 2021–2030 ($ MILLION)
EXHIBIT 91 SWITZERLAND AI IN DRUG DISCOVERY MARKET 2021–2030 ($ MILLION)
EXHIBIT 92 FRANCE AI IN DRUG DISCOVERY MARKET 2021–2030 ($ MILLION)
EXHIBIT 93 ITALY AI IN DRUG DISCOVERY MARKET 2021–2030 ($ MILLION)
EXHIBIT 94 SPAIN AI IN DRUG DISCOVERY MARKET 2021–2030 ($ MILLION)
EXHIBIT 95 NETHERLANDS AI IN DRUG DISCOVERY MARKET 2021–2030 ($ MILLION)
EXHIBIT 96 APAC AI IN DRUG DISCOVERY MARKET: KEY COUNTRIES IN 2024 ($ MILLION)
EXHIBIT 97 APAC AI IN DRUG DISCOVERY MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 98 APAC AI IN DRUG DISCOVERY MARKET 2021–2030 ($ MILLION)
EXHIBIT 99 INCREMENTAL GROWTH IN APAC 2024 & 2030
EXHIBIT 100 CHINA AI IN DRUG DISCOVERY MARKET 2021–2030 ($ MILLION)
EXHIBIT 101 JAPAN AI IN DRUG DISCOVERY MARKET 2021–2030 ($ MILLION)
EXHIBIT 102 INDIA AI IN DRUG DISCOVERY MARKET 2021–2030 ($ MILLION)
EXHIBIT 103 SOUTH KOREA AI IN DRUG DISCOVERY MARKET 2021–2030 ($ MILLION)
EXHIBIT 104 AUSTRALIA AI IN DRUG DISCOVERY MARKET 2021–2030 ($ MILLION)
EXHIBIT 105 LATIN AMERICA AI IN DRUG DISCOVERY MARKET: KEY COUNTRIES IN 2024 ($ MILLION)
EXHIBIT 106 LATIN AMERICA AI IN DRUG DISCOVERY MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 107 LATIN AMERICA AI IN DRUG DISCOVERY MARKET 2021–2030 ($ MILLION)
EXHIBIT 108 INCREMENTAL GROWTH IN LATIN AMERICA 2024 & 2030
EXHIBIT 109 BRAZIL AI IN DRUG DISCOVERY MARKET 2021–2030 ($ MILLION)
EXHIBIT 110 MEXICO AI IN DRUG DISCOVERY MARKET 2021–2030 ($ MILLION)
EXHIBIT 111 ARGENTINA AI IN DRUG DISCOVERY MARKET 2021–2030 ($ MILLION)
EXHIBIT 112 COLOMBIA AI IN DRUG DISCOVERY MARKET 2021–2030 ($ MILLION)
EXHIBIT 113 MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET: KEY COUNTRIES IN 2024 ($ MILLION)
EXHIBIT 114 MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 115 MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET 2021–2030 ($ MILLION)
EXHIBIT 116 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA 2024 & 2030
EXHIBIT 117 TURKEY AI IN DRUG DISCOVERY MARKET 2021–2030 ($ MILLION)
EXHIBIT 118 SOUTH AFRICA AI IN DRUG DISCOVERY MARKET 2021–2030 ($ MILLION)
EXHIBIT 119 SAUDI ARABIA AI IN DRUG DISCOVERY MARKET 2021–2030 ($ MILLION)
EXHIBIT 120 UAE AI IN DRUG DISCOVERY MARKET 2021–2030 ($ MILLION)
EXHIBIT 121 KEY CAVEATS
LIST OF TABLES
TABLE 1 GLOBAL DRUG REPURPOSING AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 2 GLOBAL DRUG REPURPOSING AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 3 GLOBAL DRUG SCREENING AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 4 GLOBAL DRUG SCREENING AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 5 GLOBAL DRUG DESIGN & OPTIMIZATION AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 6 GLOBAL DRUG DESIGN & OPTIMIZATION AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 7 GLOBAL OTHERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 8 GLOBAL OTHERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 9 GLOBAL ONCOLOGICAL DISORDERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 10 GLOBAL ONCOLOGICAL DISORDERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 11 GLOBAL CNS DISORDERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 12 GLOBAL CNS DISORDERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 13 GLOBAL INFECTIOUS DISEASES AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 14 GLOBAL INFECTIOUS DISEASES AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 15 GLOBAL IMMUNOLOGICAL DISORDERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 16 GLOBAL IMMUNOLOGICAL DISORDERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 17 GLOBAL CARDIOVASCULAR DISORDERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 18 GLOBAL CARDIOVASCULAR DISORDERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 19 GLOBAL GASTROINTESTINAL DISORDERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 20 GLOBAL GASTROINTESTINAL DISORDERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 21 GLOBAL OTHERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 22 GLOBAL OTHERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 23 GLOBAL SMALL MOLECULE AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 24 GLOBAL SMALL MOLECULE AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 25 GLOBAL BIOLOGICS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 26 GLOBAL BIOLOGICS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 27 GLOBAL MACHINE LEARNING AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 28 GLOBAL MACHINE LEARNING AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 29 GLOBAL DEEP LEARNING AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 30 GLOBAL DEEP LEARNING AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 31 GLOBAL NATURAL LANGUAGE PROCESSING AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 32 GLOBAL NATURAL LANGUAGE PROCESSING AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 33 GLOBAL OTHERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 34 GLOBAL OTHERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 35 GLOBAL PHARMA & BIOTECH COMPANIES AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 36 GLOBAL PHARMA & BIOTECH COMPANIES AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 37 GLOBAL CROS & CDMOS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 38 GLOBAL CROS & CDMOS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 39 GLOBAL OTHERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 40 GLOBAL OTHERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 41 NORTH AMERICA AI IN DRUG DISCOVERY MARKET BY APPLICATION 2024−2030 ($ MILLION)
TABLE 42 NORTH AMERICA AI IN DRUG DISCOVERY MARKET BY APPLICATION 2024−2030 (%)
TABLE 43 NORTH AMERICA AI IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA 2024−2030 ($ MILLION)
TABLE 44 NORTH AMERICA AI IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA 2024−2030 (%)
TABLE 45 NORTH AMERICA AI IN DRUG DISCOVERY MARKET BY DRUG TYPE 2024−2030 ($ MILLION)
TABLE 46 NORTH AMERICA AI IN DRUG DISCOVERY MARKET BY DRUG TYPE 2024−2030 (%)
TABLE 47 NORTH AMERICA AI IN DRUG DISCOVERY MARKET BY TECHNOLOGY 2024−2030 ($ MILLION)
TABLE 48 NORTH AMERICA AI IN DRUG DISCOVERY MARKET BY TECHNOLOGY 2024−2030 (%)
TABLE 49 NORTH AMERICA AI IN DRUG DISCOVERY MARKET BY END-USER 2024−2030 ($ MILLION)
TABLE 50 NORTH AMERICA AI IN DRUG DISCOVERY MARKET BY END-USER 2024−2030 (%)
TABLE 51 EUROPE AI IN DRUG DISCOVERY MARKET BY APPLICATION 2024−2030 ($ MILLION)
TABLE 52 EUROPE AI IN DRUG DISCOVERY MARKET BY APPLICATION 2024−2030 (%)
TABLE 53 EUROPE AI IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA 2024−2030 ($ MILLION)
TABLE 54 EUROPE AI IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA 2024−2030 (%)
TABLE 55 EUROPE AI IN DRUG DISCOVERY MARKET BY DRUG TYPE 2024−2030 ($ MILLION)
TABLE 56 EUROPE AI IN DRUG DISCOVERY MARKET BY DRUG TYPE 2024−2030 (%)
TABLE 57 EUROPE AI IN DRUG DISCOVERY MARKET BY TECHNOLOGY 2024−2030 ($ MILLION)
TABLE 58 EUROPE AI IN DRUG DISCOVERY MARKET BY TECHNOLOGY 2024−2030 (%)
TABLE 59 EUROPE AI IN DRUG DISCOVERY MARKET BY END-USER 2024−2030 ($ MILLION)
TABLE 60 EUROPE AI IN DRUG DISCOVERY MARKET BY END-USER 2024−2030 (%)
TABLE 61 APAC AI IN DRUG DISCOVERY MARKET BY APPLICATION 2024−2030 ($ MILLION)
TABLE 62 APAC AI IN DRUG DISCOVERY MARKET BY APPLICATION 2024−2030 (%)
TABLE 63 APAC AI IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA 2024−2030 ($ MILLION)
TABLE 64 APAC AI IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA 2024−2030 (%)
TABLE 65 APAC AI IN DRUG DISCOVERY MARKET BY DRUG TYPE 2024−2030 ($ MILLION)
TABLE 66 APAC AI IN DRUG DISCOVERY MARKET BY DRUG TYPE 2024−2030 (%)
TABLE 67 APAC AI IN DRUG DISCOVERY MARKET BY TECHNOLOGY 2024−2030 ($ MILLION)
TABLE 68 APAC AI IN DRUG DISCOVERY MARKET BY TECHNOLOGY 2024−2030 (%)
TABLE 69 APAC AI IN DRUG DISCOVERY MARKET BY END-USER 2024−2030 ($ MILLION)
TABLE 70 APAC AI IN DRUG DISCOVERY MARKET BY END-USER 2024−2030 (%)
TABLE 71 LATIN AMERICA AI IN DRUG DISCOVERY MARKET BY APPLICATION 2024−2030 ($ MILLION)
TABLE 72 LATIN AMERICA AI IN DRUG DISCOVERY MARKET BY APPLICATION 2024−2030 (%)
TABLE 73 LATIN AMERICA AI IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA 2024−2030 ($ MILLION)
TABLE 74 LATIN AMERICA AI IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA 2024−2030 (%)
TABLE 75 LATIN AMERICA AI IN DRUG DISCOVERY MARKET BY DRUG TYPE 2024−2030 ($ MILLION)
TABLE 76 LATIN AMERICA AI IN DRUG DISCOVERY MARKET BY DRUG TYPE 2024−2030 (%)
TABLE 77 LATIN AMERICA AI IN DRUG DISCOVERY MARKET BY TECHNOLOGY 2024−2030 ($ MILLION)
TABLE 78 LATIN AMERICA AI IN DRUG DISCOVERY MARKET BY TECHNOLOGY 2024−2030 (%)
TABLE 79 LATIN AMERICA AI IN DRUG DISCOVERY MARKET BY END-USER 2024−2030 ($ MILLION)
TABLE 80 LATIN AMERICA AI IN DRUG DISCOVERY MARKET BY END-USER 2024−2030 (%)
TABLE 81 MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET BY APPLICATION 2024−2030 ($ MILLION)
TABLE 82 MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET BY APPLICATION 2024−2030 (%)
TABLE 83 MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA 2024−2030 ($ MILLION)
TABLE 84 MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA 2024−2030 (%)
TABLE 85 MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET BY DRUG TYPE 2024−2030 ($ MILLION)
TABLE 86 MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET BY DRUG TYPE 2024−2030 (%)
TABLE 87 MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET BY TECHNOLOGY 2024−2030 ($ MILLION)
TABLE 88 MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET BY TECHNOLOGY 2024−2030 (%)
TABLE 89 MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET BY END-USER 2024−2030 ($ MILLION)
TABLE 90 MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET BY END-USER 2024−2030 (%)
TABLE 91 ATOMWISE: MAJOR PRODUCT OFFERINGS
TABLE 92 AMAZON WEB SERVICES (AWS): MAJOR PRODUCT OFFERINGS
TABLE 93 BENEVOLENTAI: MAJOR PRODUCT OFFERINGS
TABLE 94 GOOGLE: MAJOR PRODUCT OFFERINGS
TABLE 95 IBM: MAJOR PRODUCT OFFERINGS
TABLE 96 INSILICO MEDICINE: MAJOR PRODUCT OFFERINGS
TABLE 97 MICROSOFT: MAJOR PRODUCT OFFERINGS
TABLE 98 NVIDIA: MAJOR PRODUCT OFFERINGS
TABLE 99 RECURSION PHARMACEUTICALS: MAJOR PRODUCT OFFERINGS
TABLE 100 ABCELLERA: MAJOR PRODUCT OFFERINGS
TABLE 101 AITIA: MAJOR PRODUCT OFFERINGS
TABLE 102 BENCHSCI: MAJOR PRODUCT OFFERINGS
TABLE 103 BIOSYMETRICS: MAJOR PRODUCT OFFERINGS
TABLE 104 BPGBIO: MAJOR PRODUCT OFFERINGS
TABLE 105 CENTELLA: MAJOR PRODUCT OFFERINGS
TABLE 106 ENVISAGENICS: MAJOR PRODUCT OFFERINGS
TABLE 107 EVAXION BIOTECH A/S: MAJOR PRODUCT OFFERINGS
TABLE 108 IKTOS: MAJOR PRODUCT OFFERINGS
TABLE 109 ILLUMINA: MAJOR PRODUCT OFFERINGS
TABLE 110 INSITRO: MAJOR PRODUCT OFFERINGS
TABLE 111 MERCK KGAA: MAJOR PRODUCT OFFERINGS
TABLE 112 MODEL MEDICINE: MAJOR PRODUCT OFFERINGS
TABLE 113 NUMEDII: MAJOR PRODUCT OFFERINGS
TABLE 114 OWKIN: MAJOR PRODUCT OFFERINGS
TABLE 115 PREDICTIVE ONCOLOGY: MAJOR PRODUCT OFFERINGS
TABLE 116 RELAY THERAPEUTICS: MAJOR PRODUCT OFFERINGS
TABLE 117 STANDIGM: MAJOR PRODUCT OFFERINGS
TABLE 118 VALO HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 119 VERGE GENOMICS: MAJOR PRODUCT OFFERINGS
TABLE 120 XTALPI: MAJOR PRODUCT OFFERINGS
TABLE 121 GLOBAL AI IN DRUG DISCOVERY MARKET BY APPLICATION 2024−2030 ($ MILLION)
TABLE 122 GLOBAL AI IN DRUG DISCOVERY MARKET BY APPLICATION 2024−2030 (%)
TABLE 123 NORTH AMERICA AI IN DRUG DISCOVERY MARKET BY APPLICATION 2024−2030 ($ MILLION)
TABLE 124 NORTH AMERICA AI IN DRUG DISCOVERY MARKET BY APPLICATION 2024−2030 (%)
TABLE 125 EUROPE AI IN DRUG DISCOVERY MARKET BY APPLICATION 2024−2030 ($ MILLION)
TABLE 126 EUROPE AI IN DRUG DISCOVERY MARKET BY APPLICATION 2024−2030 (%)
TABLE 127 APAC AI IN DRUG DISCOVERY MARKET BY APPLICATION 2024−2030 ($ MILLION)
TABLE 128 APAC AI IN DRUG DISCOVERY MARKET BY APPLICATION 2024−2030 (%)
TABLE 129 LATIN AMERICA AI IN DRUG DISCOVERY MARKET BY APPLICATION 2024−2030 ($ MILLION)
TABLE 130 LATIN AMERICA AI IN DRUG DISCOVERY MARKET BY APPLICATION 2024−2030 (%)
TABLE 131 MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET BY APPLICATION 2024−2030 ($ MILLION)
TABLE 132 MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET BY APPLICATION 2024−2030 (%)
TABLE 133 GLOBAL AI IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA 2024−2030 ($ MILLION)
TABLE 134 GLOBAL AI IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA 2024−2030 (%)
TABLE 135 NORTH AMERICA AI IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA 2024−2030 ($ MILLION)
TABLE 136 NORTH AMERICA AI IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA 2024−2030 (%)
TABLE 137 EUROPE AI IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA 2024−2030 ($ MILLION)
TABLE 138 EUROPE AI IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA 2024−2030 (%)
TABLE 139 APAC AI IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA 2024−2030 ($ MILLION)
TABLE 140 APAC AI IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA 2024−2030 (%)
TABLE 141 LATIN AMERICA AI IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA 2024−2030 ($ MILLION)
TABLE 142 LATIN AMERICA AI IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA 2024−2030 (%)
TABLE 143 MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA 2024−2030 ($ MILLION)
TABLE 144 MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA 2024−2030 (%)
TABLE 145 GLOBAL AI IN DRUG DISCOVERY MARKET BY DRUG TYPE 2024−2030 ($ MILLION)
TABLE 146 GLOBAL AI IN DRUG DISCOVERY MARKET BY DRUG TYPE 2024−2030 (%)
TABLE 147 NORTH AMERICA AI IN DRUG DISCOVERY MARKET BY DRUG TYPE 2024−2030 ($ MILLION)
TABLE 148 NORTH AMERICA AI IN DRUG DISCOVERY MARKET BY DRUG TYPE 2024−2030 (%)
TABLE 149 EUROPE AI IN DRUG DISCOVERY MARKET BY DRUG TYPE 2024−2030 ($ MILLION)
TABLE 150 EUROPE AI IN DRUG DISCOVERY MARKET BY DRUG TYPE 2024−2030 (%)
TABLE 151 APAC AI IN DRUG DISCOVERY MARKET BY DRUG TYPE 2024−2030 ($ MILLION)
TABLE 152 APAC AI IN DRUG DISCOVERY MARKET BY DRUG TYPE 2024−2030 (%)
TABLE 153 LATIN AMERICA AI IN DRUG DISCOVERY MARKET BY DRUG TYPE 2024−2030 ($ MILLION)
TABLE 154 LATIN AMERICA AI IN DRUG DISCOVERY MARKET BY DRUG TYPE 2024−2030 (%)
TABLE 155 MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET BY DRUG TYPE 2024−2030 ($ MILLION)
TABLE 156 MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET BY DRUG TYPE 2024−2030 (%)
TABLE 157 GLOBAL AI IN DRUG DISCOVERY MARKET BY TECHNOLOGY 2024−2030 ($ MILLION)
TABLE 158 GLOBAL AI IN DRUG DISCOVERY MARKET BY TECHNOLOGY 2024−2030 (%)
TABLE 159 NORTH AMERICA AI IN DRUG DISCOVERY MARKET BY TECHNOLOGY 2024−2030 ($ MILLION)
TABLE 160 NORTH AMERICA AI IN DRUG DISCOVERY MARKET BY TECHNOLOGY 2024−2030 (%)
TABLE 161 EUROPE AI IN DRUG DISCOVERY MARKET BY TECHNOLOGY 2024−2030 ($ MILLION)
TABLE 162 EUROPE AI IN DRUG DISCOVERY MARKET BY TECHNOLOGY 2024−2030 (%)
TABLE 163 APAC AI IN DRUG DISCOVERY MARKET BY TECHNOLOGY 2024−2030 ($ MILLION)
TABLE 164 APAC AI IN DRUG DISCOVERY MARKET BY TECHNOLOGY 2024−2030 (%)
TABLE 165 LATIN AMERICA AI IN DRUG DISCOVERY MARKET BY TECHNOLOGY 2024−2030 ($ MILLION)
TABLE 166 LATIN AMERICA AI IN DRUG DISCOVERY MARKET BY TECHNOLOGY 2024−2030 (%)
TABLE 167 MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET BY TECHNOLOGY 2024−2030 ($ MILLION)
TABLE 168 MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET BY TECHNOLOGY 2024−2030 (%)
TABLE 169 GLOBAL AI IN DRUG DISCOVERY MARKET BY END-USER 2024−2030 ($ MILLION)
TABLE 170 GLOBAL AI IN DRUG DISCOVERY MARKET BY END-USER 2024−2030 (%)
TABLE 171 NORTH AMERICA AI IN DRUG DISCOVERY MARKET BY END-USER 2024−2030 ($ MILLION)
TABLE 172 NORTH AMERICA AI IN DRUG DISCOVERY MARKET BY END-USER 2024−2030 (%)
TABLE 173 EUROPE AI IN DRUG DISCOVERY MARKET BY END-USER 2024−2030 ($ MILLION)
TABLE 174 EUROPE AI IN DRUG DISCOVERY MARKET BY END-USER 2024−2030 (%)
TABLE 175 APAC AI IN DRUG DISCOVERY MARKET BY END-USER 2024−2030 ($ MILLION)
TABLE 176 APAC AI IN DRUG DISCOVERY MARKET BY END-USER 2024−2030 (%)
TABLE 177 LATIN AMERICA AI IN DRUG DISCOVERY MARKET BY END-USER 2024−2030 ($ MILLION)
TABLE 178 LATIN AMERICA AI IN DRUG DISCOVERY MARKET BY END-USER 2024−2030 (%)
TABLE 179 MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET BY END-USER 2024−2030 ($ MILLION)
TABLE 180 MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET BY END-USER 2024−2030 (%)
TABLE 181 GLOBAL AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 182 GLOBAL AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 183 GLOBAL DRUG REPURPOSING AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 184 GLOBAL DRUG REPURPOSING AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 185 GLOBAL DRUG SCREENING AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 186 GLOBAL DRUG SCREENING AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 187 GLOBAL DRUG DESIGN & OPTIMIZATION AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 188 GLOBAL DRUG DESIGN & OPTIMIZATION AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 189 GLOBAL OTHERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 190 GLOBAL OTHERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 191 GLOBAL ONCOLOGICAL DISORDERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 192 GLOBAL ONCOLOGICAL DISORDERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 193 GLOBAL CNS DISORDERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 194 GLOBAL CNS DISORDERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 195 GLOBAL INFECTIOUS DISEASES AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 196 GLOBAL INFECTIOUS DISEASES AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 197 GLOBAL IMMUNOLOGICAL DISORDERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 198 GLOBAL IMMUNOLOGICAL DISORDERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 199 GLOBAL CARDIOVASCULAR DISORDERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 200 GLOBAL CARDIOVASCULAR DISORDERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 201 GLOBAL GASTROINTESTINAL DISORDERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 202 GLOBAL GASTROINTESTINAL DISORDERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 203 GLOBAL OTHERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 204 GLOBAL OTHERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 205 GLOBAL SMALL MOLECULE AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 206 GLOBAL SMALL MOLECULE AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 207 GLOBAL BIOLOGICS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 208 GLOBAL BIOLOGICS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 209 GLOBAL MACHINE LEARNING AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 210 GLOBAL MACHINE LEARNING AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 211 GLOBAL DEEP LEARNING AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 212 GLOBAL DEEP LEARNING AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 213 GLOBAL NATURAL LANGUAGE PROCESSING AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 214 GLOBAL NATURAL LANGUAGE PROCESSING AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 215 GLOBAL OTHERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 216 GLOBAL OTHERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 217 GLOBAL PHARMA & BIOTECH COMPANIES AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 218 GLOBAL PHARMA & BIOTECH COMPANIES AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 219 GLOBAL CROS & CDMOS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 220 GLOBAL CROS & CDMOS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 221 GLOBAL OTHERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 ($ MILLION)
TABLE 222 GLOBAL OTHERS AI IN DRUG DISCOVERY MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 223 CURRENCY CONVERSION 2018−2024
1. SCOPE & COVERAGE
1.1. MARKET DEFINITION
1.1.1. INCLUSIONS
1.1.2. EXCLUSIONS
1.1.3. MARKET ESTIMATION CAVEATS
1.2. SEGMENTS COVERED & DEFINITION
1.2.1. MARKET SEGMENTATION BY APPLICATION
1.2.2. MARKET SEGMENTATION BY THERAPEUTIC AREA
1.2.3. MARKET SEGMENTATION BY DRUG TYPE
1.2.4. MARKET SEGMENTATION BY TECHNOLOGY
1.2.5. MARKET SEGMENTATION BY END-USER
1.2.6. REGIONS & COUNTRIES COVERED
1.3. MARKET DERIVATION
1.3.1. HISTORIC, BASE, & FORECAST YEARS
2. PREMIUM INSIGHTS
2.1. OPPORTUNITY POCKETS
2.2. OVERVIEW
3. MARKET AT A GLANCE
4. INTRODUCTION
4.1. OVERVIEW
5. MARKET OPPORTUNITIES & TRENDS
5.1. INTEGRATION OF AI WITH BIG DATA AND OMICS TECHNOLOGIES
5.2. INCREASE IN USE OF GENERATIVE AI MODELS
5.3. EMERGENCE OF AI-DRIVEN DRUG REPURPOSING
5.4. GROWTH IN PARTNERSHIPS BETWEEN PHARMACEUTICAL COMPANIES AND AI-FOCUSED EXPERTISE
6. MARKET GROWTH ENABLERS
6.1. ADVANCES IN COMPUTING POWER AND CLOUD TECHNOLOGIES
6.2. RISE IN R&D COSTS IN DRUG DISCOVERY
6.3. GROWTH IN VOLUME OF BIOLOGICAL AND CLINICAL DATA
6.4. INCREASE IN PREVALENCE OF CHRONIC DISEASES
7. MARKET RESTRAINTS
7.1. HIGH INITIAL COSTS OF AI IMPLEMENTATION
7.2. DATA PRIVACY & SECURITY CONCERNS
7.3. REGULATORY & ETHICAL CHALLENGES
8. MARKET LANDSCAPE
8.1. MARKET OVERVIEW
8.2. MARKET SIZE & FORECAST
8.3. FIVE FORCES ANALYSIS
8.3.1. THREAT OF NEW ENTRANTS
8.3.2. BARGAINING POWER OF SUPPLIERS
8.3.3. BARGAINING POWER OF BUYERS
8.3.4. THREAT OF SUBSTITUTES
8.3.5. COMPETITIVE RIVALRY
9. APPLICATION
9.1. MARKET SNAPSHOT & GROWTH ENGINE
9.2. MARKET OVERVIEW
9.3. DRUG REPURPOSING
9.3.1. MARKET OVERVIEW
9.3.2. MARKET SIZE & FORECAST
9.3.3. MARKET BY GEOGRAPHY
9.4. DRUG SCREENING
9.4.1. MARKET OVERVIEW
9.4.2. MARKET SIZE & FORECAST
9.4.3. MARKET BY GEOGRAPHY
9.5. DRUG DESIGN & OPTIMIZATION
9.5.1. MARKET OVERVIEW
9.5.2. MARKET SIZE & FORECAST
9.5.3. MARKET BY GEOGRAPHY
9.6. OTHERS
9.6.1. MARKET OVERVIEW
9.6.2. MARKET SIZE & FORECAST
9.6.3. MARKET BY GEOGRAPHY
10. THERAPEUTIC AREA
10.1. MARKET SNAPSHOT & GROWTH ENGINE
10.2. MARKET OVERVIEW
10.3. ONCOLOGICAL DISORDERS
10.3.1. MARKET OVERVIEW
10.3.2. MARKET SIZE & FORECAST
10.3.3. MARKET BY GEOGRAPHY
10.4. CENTRAL NERVOUS SYSTEM (CNS) DISORDERS
10.4.1. MARKET OVERVIEW
10.4.2. MARKET SIZE & FORECAST
10.4.3. MARKET BY GEOGRAPHY
10.5. INFECTIOUS DISEASES
10.5.1. MARKET OVERVIEW
10.5.2. MARKET SIZE & FORECAST
10.5.3. MARKET BY GEOGRAPHY
10.6. IMMUNOLOGICAL DISORDERS
10.6.1. MARKET OVERVIEW
10.6.2. MARKET SIZE & FORECAST
10.6.3. MARKET BY GEOGRAPHY
10.7. CARDIOVASCULAR DISORDERS (CVDS)
10.7.1. MARKET OVERVIEW
10.7.2. MARKET SIZE & FORECAST
10.7.3. MARKET BY GEOGRAPHY
10.8. GASTROINTESTINAL DISORDERS
10.8.1. MARKET OVERVIEW
10.8.2. MARKET SIZE & FORECAST
10.8.3. MARKET BY GEOGRAPHY
10.9. OTHERS
10.9.1. MARKET OVERVIEW
10.9.2. MARKET SIZE & FORECAST
10.9.3. MARKET BY GEOGRAPHY
11. DRUG TYPE
11.1. MARKET SNAPSHOT & GROWTH ENGINE
11.2. MARKET OVERVIEW
11.3. SMALL MOLECULE
11.3.1. MARKET OVERVIEW
11.3.2. MARKET SIZE & FORECAST
11.3.3. MARKET BY GEOGRAPHY
11.4. BIOLOGICS
11.4.1. MARKET OVERVIEW
11.4.2. MARKET SIZE & FORECAST
11.4.3. MARKET BY GEOGRAPHY
12. TECHNOLOGY
12.1. MARKET SNAPSHOT & GROWTH ENGINE
12.2. MARKET OVERVIEW
12.3. MACHINE LEARNING (ML)
12.3.1. MARKET OVERVIEW
12.3.2. MARKET SIZE & FORECAST
12.3.3. MARKET BY GEOGRAPHY
12.4. DEEP LEARNING
12.4.1. MARKET OVERVIEW
12.4.2. MARKET SIZE & FORECAST
12.4.3. MARKET BY GEOGRAPHY
12.5. NATURAL LANGUAGE PROCESSING (NLP)
12.5.1. MARKET OVERVIEW
12.5.2. MARKET SIZE & FORECAST
12.5.3. MARKET BY GEOGRAPHY
12.6. OTHERS
12.6.1. MARKET OVERVIEW
12.6.2. MARKET SIZE & FORECAST
12.6.3. MARKET BY GEOGRAPHY
13. END-USER
13.1. MARKET SNAPSHOT & GROWTH ENGINE
13.2. MARKET OVERVIEW
13.3. PHARMA & BIOTECH COMPANIES
13.3.1. MARKET OVERVIEW
13.3.2. MARKET SIZE & FORECAST
13.3.3. MARKET BY GEOGRAPHY
13.4. CONTRACT RESEARCH ORGANIZATIONS (CROS) & CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS (CDMOS)
13.4.1. MARKET OVERVIEW
13.4.2. MARKET SIZE & FORECAST
13.4.3. MARKET BY GEOGRAPHY
13.5. OTHERS
13.5.1. MARKET OVERVIEW
13.5.2. MARKET SIZE & FORECAST
13.5.3. MARKET BY GEOGRAPHY
14. GEOGRAPHY
14.1. MARKET SNAPSHOT & GROWTH ENGINE
14.2. GEOGRAPHIC OVERVIEW
15. NORTH AMERICA
15.1. MARKET OVERVIEW
15.2. MARKET SIZE & FORECAST
15.2.1. APPLICATION
15.2.2. THERAPEUTIC AREA
15.2.3. DRUG TYPE
15.2.4. TECHNOLOGY
15.2.5. END-USER
15.3. KEY COUNTRIES
15.3.1. US: MARKET SIZE & FORECAST
15.3.2. CANADA: MARKET SIZE & FORECAST
16. EUROPE
16.1. MARKET OVERVIEW
16.2. MARKET SIZE & FORECAST
16.2.1. APPLICATION
16.2.2. THERAPEUTIC AREA
16.2.3. DRUG TYPE
16.2.4. TECHNOLOGY
16.2.5. END-USER
16.3. KEY COUNTRIES
16.3.1. GERMANY: MARKET SIZE & FORECAST
16.3.2. UK: MARKET SIZE & FORECAST
16.3.3. SWITZERLAND: MARKET SIZE & FORECAST
16.3.4. FRANCE: MARKET SIZE & FORECAST
16.3.5. ITALY: MARKET SIZE & FORECAST
16.3.6. SPAIN: MARKET SIZE & FORECAST
16.3.7. NETHERLANDS: MARKET SIZE & FORECAST
17. APAC
17.1. MARKET OVERVIEW
17.2. MARKET SIZE & FORECAST
17.2.1. APPLICATION
17.2.2. THERAPEUTIC AREA
17.2.3. DRUG TYPE
17.2.4. TECHNOLOGY
17.2.5. END-USER
17.3. KEY COUNTRIES
17.3.1. CHINA: MARKET SIZE & FORECAST
17.3.2. JAPAN: MARKET SIZE & FORECAST
17.3.3. INDIA: MARKET SIZE & FORECAST
17.3.4. SOUTH KOREA: MARKET SIZE & FORECAST
17.3.5. AUSTRALIA: MARKET SIZE & FORECAST
18. LATIN AMERICA
18.1. MARKET OVERVIEW
18.2. MARKET SIZE & FORECAST
18.2.1. APPLICATION
18.2.2. THERAPEUTIC AREA
18.2.3. DRUG TYPE
18.2.4. TECHNOLOGY
18.2.5. END-USER
18.3. KEY COUNTRIES
18.3.1. BRAZIL: MARKET SIZE & FORECAST
18.3.2. MEXICO: MARKET SIZE & FORECAST
18.3.3. ARGENTINA: MARKET SIZE & FORECAST
18.3.4. COLOMBIA: MARKET SIZE & FORECAST
19. MIDDLE EAST & AFRICA
19.1. MARKET OVERVIEW
19.2. MARKET SIZE & FORECAST
19.2.1. APPLICATION
19.2.2. THERAPEUTIC AREA
19.2.3. DRUG TYPE
19.2.4. TECHNOLOGY
19.2.5. END-USER
19.3. KEY COUNTRIES
19.3.1. TURKEY: MARKET SIZE & FORECAST
19.3.2. SOUTH AFRICA: MARKET SIZE & FORECAST
19.3.3. SAUDI ARABIA: MARKET SIZE & FORECAST
19.3.4. UAE: MARKET SIZE & FORECAST
20. COMPETITIVE LANDSCAPE
20.1. COMPETITION OVERVIEW
20.2. MARKET SHARE ANALYSIS
20.2.1. ATOMWISE
20.2.2. AMAZON WEB SERVICES (AWS)
20.2.3. BENEVOLENTAI
20.2.4. GOOGLE
20.2.5. IBM
20.2.6. INSILICO MEDICINE
20.2.7. MICROSOFT
20.2.8. NVIDIA
20.2.9. RECURSION PHARMACEUTICALS
21. KEY COMPANY PROFILES
21.1. ATOMWISE
21.1.1. BUSINESS OVERVIEW
21.1.2. PRODUCT OFFERINGS
21.1.3. KEY STRATEGIES
21.1.4. KEY STRENGTHS
21.1.5. KEY OPPORTUNITIES
21.2. AMAZON WEB SERVICES (AWS)
21.2.1. BUSINESS OVERVIEW
21.2.2. PRODUCT OFFERINGS
21.2.3. KEY STRATEGIES
21.2.4. KEY STRENGTHS
21.2.5. KEY OPPORTUNITIES
21.3. BENEVOLENTAI
21.3.1. BUSINESS OVERVIEW
21.3.2. PRODUCT OFFERINGS
21.3.3. KEY STRATEGIES
21.3.4. KEY STRENGTHS
21.3.5. KEY OPPORTUNITIES
21.4. GOOGLE
21.4.1. BUSINESS OVERVIEW
21.4.2. PRODUCT OFFERINGS
21.4.3. KEY STRATEGIES
21.4.4. KEY STRENGTHS
21.4.5. KEY OPPORTUNITIES
21.5. IBM
21.5.1. BUSINESS OVERVIEW
21.5.2. PRODUCT OFFERINGS
21.5.3. KEY STRATEGIES
21.5.4. KEY STRENGTHS
21.5.5. KEY OPPORTUNITIES
21.6. INSILICO MEDICINE
21.6.1. BUSINESS OVERVIEW
21.6.2. PRODUCT OFFERINGS
21.6.3. KEY STRATEGIES
21.6.4. KEY STRENGTHS
21.6.5. KEY OPPORTUNITIES
21.7. MICROSOFT
21.7.1. BUSINESS OVERVIEW
21.7.2. PRODUCT OFFERINGS
21.7.3. KEY STRATEGIES
21.7.4. KEY STRENGTHS
21.7.5. KEY OPPORTUNITIES
21.8. NVIDIA
21.8.1. BUSINESS OVERVIEW
21.8.2. PRODUCT OFFERINGS
21.8.3. KEY STRATEGIES
21.8.4. KEY STRENGTHS
21.8.5. KEY OPPORTUNITIES
21.9. RECURSION PHARMACEUTICALS
21.9.1. BUSINESS OVERVIEW
21.9.2. PRODUCT OFFERINGS
21.9.3. KEY STRATEGIES
21.9.4. KEY STRENGTHS
21.9.5. KEY OPPORTUNITIES
22. OTHER PROMINENT VENDORS
22.1. ABCELLERA
22.1.1. BUSINESS OVERVIEW
22.1.2. PRODUCT OFFERINGS
22.2. AITIA
22.2.1. BUSINESS OVERVIEW
22.2.2. PRODUCT OFFERINGS
22.3. BENCHSCI
22.3.1. BUSINESS OVERVIEW
22.3.2. PRODUCT OFFERINGS
22.4. BIOSYMETRICS
22.4.1. BUSINESS OVERVIEW
22.4.2. PRODUCT OFFERINGS
22.5. BPGBIO
22.5.1. BUSINESS OVERVIEW
22.5.2. PRODUCT OFFERINGS
22.6. CENTELLA
22.6.1. BUSINESS OVERVIEW
22.6.2. PRODUCT OFFERINGS
22.7. ENVISAGENICS
22.7.1. BUSINESS OVERVIEW
22.7.2. PRODUCT OFFERINGS
22.8. EVAXION BIOTECH A/S
22.8.1. BUSINESS OVERVIEW
22.8.2. PRODUCT OFFERINGS
22.9. IKTOS
22.9.1. BUSINESS OVERVIEW
22.9.2. PRODUCT OFFERINGS
22.10. ILLUMINA
22.10.1. BUSINESS OVERVIEW
22.10.2. PRODUCT OFFERINGS
22.11. INSITRO
22.11.1. BUSINESS OVERVIEW
22.11.2. PRODUCT OFFERINGS
22.12. MERCK KGAA
22.12.1. BUSINESS OVERVIEW
22.12.2. PRODUCT OFFERINGS
22.13. MODEL MEDICINE
22.13.1. BUSINESS OVERVIEW
22.13.2. PRODUCT OFFERINGS
22.14. NUMEDII
22.14.1. BUSINESS OVERVIEW
22.14.2. PRODUCT OFFERINGS
22.15. OWKIN
22.15.1. BUSINESS OVERVIEW
22.15.2. PRODUCT OFFERINGS
22.16. PREDICTIVE ONCOLOGY
22.16.1. BUSINESS OVERVIEW
22.16.2. PRODUCT OFFERINGS
22.17. RELAY THERAPEUTICS
22.17.1. BUSINESS OVERVIEW
22.17.2. PRODUCT OFFERINGS
22.18. STANDIGM
22.18.1. BUSINESS OVERVIEW
22.18.2. PRODUCT OFFERINGS
22.19. VALO HEALTH
22.19.1. BUSINESS OVERVIEW
22.19.2. PRODUCT OFFERINGS
22.20. VERGE GENOMICS
22.20.1. BUSINESS OVERVIEW
22.20.2. PRODUCT OFFERINGS
22.21. XTALPI
22.21.1. BUSINESS OVERVIEW
22.21.2. PRODUCT OFFERINGS
23. REPORT SUMMARY
23.1. KEY TAKEAWAYS
23.2. STRATEGIC RECOMMENDATIONS
24. QUANTITATIVE SUMMARY
24.1. MARKET BY APPLICATION
24.1.1. NORTH AMERICA
24.1.2. EUROPE
24.1.3. APAC
24.1.4. LATIN AMERICA
24.1.5. MIDDLE EAST & AFRICA
24.2. MARKET BY THERAPEUTIC AREA
24.2.1. NORTH AMERICA
24.2.2. EUROPE
24.2.3. APAC
24.2.4. LATIN AMERICA
24.2.5. MIDDLE EAST & AFRICA
24.3. MARKET BY DRUG TYPE
24.3.1. NORTH AMERICA
24.3.2. EUROPE
24.3.3. APAC
24.3.4. LATIN AMERICA
24.3.5. MIDDLE EAST & AFRICA
24.4. MARKET BY TECHNOLOGY
24.4.1. NORTH AMERICA
24.4.2. EUROPE
24.4.3. APAC
24.4.4. LATIN AMERICA
24.4.5. MIDDLE EAST & AFRICA
24.5. MARKET BY END-USER
24.5.1. NORTH AMERICA
24.5.2. EUROPE
24.5.3. APAC
24.5.4. LATIN AMERICA
24.5.5. MIDDLE EAST & AFRICA
24.6. MARKET BY GEOGRAPHY
24.6.1. DRUG REPURPOSING
24.6.2. DRUG SCREENING
24.6.3. DRUG DESIGN & OPTIMIZATION
24.6.4. OTHER APPLICATIONS
24.6.5. ONCOLOGICAL DISORDERS
24.6.6. CNS DISORDERS
24.6.7. INFECTIOUS DISEASES
24.6.8. IMMUNOLOGICAL DISORDERS
24.6.9. CARDIOVASCULAR DISORDERS
24.6.10. GASTROINTESTINAL DISORDERS
24.6.11. OTHER THERAPEUTIC AREAS
24.6.12. SMALL MOLECULE
24.6.13. BIOLOGICS
24.6.14. MACHINE LEARNING
24.6.15. DEEP LEARNING
24.6.16. NATURAL LANGUAGE PROCESSING
24.6.17. OTHER TECHNOLOGIES
24.6.18. PHARMA & BIOTECH COMPANIES
24.6.19. CROS & CDMOS
24.6.20. OTHER END-USERS
25. APPENDIX
25.1. RESEARCH METHODOLOGY
25.2. RESEARCH PROCESS
25.3. REPORT ASSUMPTIONS & CAVEATS
25.3.1. KEY CAVEATS
25.3.2. CURRENCY CONVERSION
25.4. ABBREVIATIONS
Select a license type that suits your business needs
Single User Licence
- Report accessible by one user only
- Free 10% or 3 days of customization
- Free post-sale service assistance
- Continuous support through email
5 User Licence
- Report accessible by 5 users within the organization
- Free 15% or 4.5 days of customization
- Continuous support through email and telephone
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
- Free Datasheet worth $1500
- Report accessible by the entire organization
- Free 20% or 6 days of customization
- Free post-sale service assistance
- Continuous support through email and telephone
- Direct access to lead analysts
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
- Report accessible by 1 user only
- Free 15% or 32 hours of customization
- Free post-sale service assistance
- Direct access to lead analysts
Frequently Asked Questions
How big is the global AI in drug discovery market?
What is the growth rate of the global AI in drug discovery market?
Which region dominates the global AI in drug discovery market share?
What are the significant trends in the AI in drug discovery industry?
Who are the key players in the global AI in drug discovery market?
Artificial Intelligence (AI) in Drug Discovery Market Report
Other RELATED Reports
Global Artificial Intelligence (AI) In Genomics Market - Focused Insights 2024-2029
Published : July 2024
